首页> 美国卫生研究院文献>Biomedicines >From Mitochondria to Atherosclerosis: The Inflammation Path
【2h】

From Mitochondria to Atherosclerosis: The Inflammation Path

机译:从线粒体到动脉粥样硬化:炎症路径

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inflammation is a key process in metazoan organisms due to its relevance for innate defense against infections and tissue damage. However, inflammation is also implicated in pathological processes such as atherosclerosis. Atherosclerosis is a chronic inflammatory disease of the arterial wall where unstable atherosclerotic plaque rupture causing platelet aggregation and thrombosis may compromise the arterial lumen, leading to acute or chronic ischemic syndromes. In this review, we will focus on the role of mitochondria in atherosclerosis while keeping inflammation as a link. Mitochondria are the main source of cellular energy. Under stress, mitochondria are also capable of controlling inflammation through the production of reactive oxygen species (ROS) and the release of mitochondrial components, such as mitochondrial DNA (mtDNA), into the cytoplasm or into the extracellular matrix, where they act as danger signals when recognized by innate immune receptors. Primary or secondary mitochondrial dysfunctions are associated with the initiation and progression of atherosclerosis by elevating the production of ROS, altering mitochondrial dynamics and energy supply, as well as promoting inflammation. Knowing and understanding the pathways behind mitochondrial-based inflammation in atheroma progression is essential to discovering alternative or complementary treatments.
机译:由于其与对抗感染和组织损伤的先生防御的相关性,炎症是甲卓生物的关键过程。然而,炎症也涉及病理过程,例如动脉粥样硬化。动脉粥样硬化是动脉壁的慢性炎症疾病,其中血栓聚集和血栓形成的不稳定动脉粥样硬化斑块破裂可能会损害动脉内腔,导致急性或慢性缺血综合征。在本综述中,我们将专注于线粒体在动脉粥样硬化中的作用,同时保持炎症作为链接。线粒体是细胞能量的主要来源。在应力下,线粒体也能够通过生产活性氧物质(ROS)和线粒体组分的释放,例如线粒体DNA(MTDNA),进入细胞质或进入细胞外基质的线粒体组分,它们充当危险信号当被先天的免疫受体识别时。初级或二级线粒体功能障碍通过提高ROS,改变线粒体动力学和能量供应以及促进炎症来与动脉粥样硬化的起始和进展相关。了解和理解线粒体进展中的线粒体炎症背后的途径对于发现替代或互补治疗至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号